The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 14, 2016

Filed:

Dec. 31, 2010
Applicants:

David S. Peabody, Albuquerque, NM (US);

Bryce Chackerian, Albuquerque, NM (US);

Inventors:

David S. Peabody, Albuquerque, NM (US);

Bryce Chackerian, Albuquerque, NM (US);

Assignee:

STC.UNM, Albuquerque, NM (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C40B 40/08 (2006.01); C12N 7/00 (2006.01); A61K 39/07 (2006.01); A61K 39/12 (2006.01); C12N 15/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); A61K 39/07 (2013.01); A61K 39/12 (2013.01); C12N 15/1037 (2013.01); A61K 2039/5258 (2013.01); C12N 2710/20034 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16134 (2013.01); C12N 2795/16023 (2013.01); C12N 2795/18023 (2013.01); C40B 40/08 (2013.01);
Abstract

The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on VLPs, especially MS2 VLPS over a wide range, from few than one—on average—to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of MS2 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates MS2 niRNA. Nucleic acid constructs are also disclosed which are useful in the expression of virus-like particles comprised of a coat polypeptide of PP7 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates PP7 mRNA.


Find Patent Forward Citations

Loading…